Genistein prevents the decrease in ganglioside levels induced by amyloid-beta in the frontal cortex of rats.
Fernanda Dos Santos Petry1, Juliana Bender Hoppe1, Caroline Peres Klein1
1Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Neurological Research
|January 21, 2022
Summary
Genistein treatment prevented amyloid-beta (Aβ) induced decreases in frontal cortex gangliosides in rats. This suggests genistein may offer neuroprotection against Aβ toxicity by preserving key lipids.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Amyloid-beta (Aβ) peptide is implicated in neurodegenerative diseases.
- Lipid alterations, particularly in gangliosides, may contribute to Aβ toxicity.
- Genistein is a soy isoflavone with potential therapeutic properties.
Purpose of the Study:
- To investigate the effects of Aβ toxicity and genistein treatment on lipid composition in the rat frontal cortex.
- To determine if genistein can mitigate Aβ-induced changes in gangliosides, phospholipids, and cholesterol.
Main Methods:
- An in vivo rat model of Aβ toxicity was established using intracerebroventricular infusions.
- Rats received Aβ1-42 and/or genistein treatment for 10 days.
- Lipid extraction and quantification of gangliosides, phospholipids, and cholesterol in the frontal cortex were performed.
Main Results:
- Aβ infusion significantly decreased overall ganglioside concentration and specific species (GD1b, GQ1b).
- Genistein treatment effectively prevented the reduction in ganglioside levels.
- No significant changes were observed in phospholipid or cholesterol content.
Conclusions:
- Aβ toxicity alters frontal cortex ganglioside composition in rats.
- Genistein demonstrates neuroprotective potential by preserving ganglioside levels against Aβ-induced damage.
- These findings highlight gangliosides as potential targets for genistein's beneficial effects in neuroprotection.
